Citi, acting through Citibank N.A., has been appointed by Renalytix AI PLC (“Renalytix AI”) – an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs – to act as depositary bank for its American Depositary Receipt (“ADR”) programme.
Renalytix AI’s American Depositary Shares (“ADS”) trade on the Nasdaq Global Market under the symbol “RNLX”. Each ADS represents two common shares of the company. Renalytix AI underlying common shares are listed and trade on the AIM market of London Stock Exchange under the symbol “RENX”.
Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: “We look forward to supporting Renalytix AI’s ADR programme and expanding the company’s investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network.”
